$150K — $200K *
NGM Biopharmaceuticals, Inc. is a leader in research elucidating the central role that myeloid cells play in creating a suppressive environment around many solid tumors that restricts antitumor immunity. Through systematic screening, NGM was able to identify the suppressive receptors that are most highly enriched in myeloid cells. An additional strength of our research group is the design and construction of highly potent antibodies and other biologics. Pairing these capabilities with the identification of these suppressive receptors on tumor-associate myeloid cells has produced a promising pipeline of new medicines aimed at treating solid tumors. Three oncology molecules produced from this approach include NGM707 (anti-ILT2/ILT4 dual acting antibody), NGM831 (anti-ILT3), NGM438 (anti-LAIR1). In addition, NGM120 (anti-GFRAL) emanates from our metabolic research and autonomic nervous system regulation of the immune system.
NGM Biopharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing the next generation of medicines for the treatment of serious diseases. Our experienced scientific team has joined forces with an impressive group of industry professionals, Nobel Laureates and other distinguished researchers to build a company where innovation and cutting-edge science has provided the foundation for a robust drug discovery engine that has a track record of generating one new IND candidate per year. NGM’s current pipeline of clinical-stage programs consists of five drug candidates targeting cancer, retinal diseases, and liver and metabolic diseases. These programs include MK-3655 in a phase 2b clinical study in patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis stage 2 or 3 (F2/3), being run by our partner, Merck, aldafermin in a Phase 2b clinical study in NASH patients with F4 liver fibrosis and compensated cirrhosis, NGM621 in a Phase 2 study in geographic atrophy (GA) secondary to age-related macular degeneration (AMD), NGM120 in a Phase 2 study for the treatment of metastatic pancreatic cancer, and NGM707 in a Phase 1/2 study for the treatment of advanced solid tumors.
NGMBio is seeking a talented and motivated Senior Medical Director or Medical Director to join our Clinical Development Oncology team. Qualified candidates will be essential contributors to the scientific, clinical, and operational scope of clinical development programs with emphasis on protocol-specific activities. This individual will participate and significantly contribute to the whole Clinical Development Plan (CDP) from Proof-of-Concept (POC) studies to registrational studies. This role will help drive the design, planning and implementation of study protocols for the assigned Oncology program(s), starting from playing a key role in supporting related regulatory activities to operational execution of the study, including monitoring of clinical trials, assisting with data interpretation and communication with both internal and external stakeholders. To achieve these goals, candidates will work cross-functionally with the product development team (PDT) and the Clinical Study Team to support various deliverables necessary for effective and efficient execution for the assigned molecule(s) / indication(s).
Specific Responsibilities for Role:
Education, Experience, and Skills Required:
Valid through: 11/16/2021
$100K — $150K *
5 days ago
$120K — $170K + $25K bonus *
3 days ago